Back
KYP
Kinatico Ltd
🇦🇺 ASX
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 36.67%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
7
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Kinatico Ltd. engages in the provision of screening and verification services. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-09-08. The Company’s solutions comprise pre-employment screening, verification services and workforce compliance management internationally. The company provides real-time workforce compliance management via its core software-as-a-service RegTech solution. By combining certifications and compliance data with business policy and legislative requirements, the Company enables scalable compliance monitoring spanning preemployment to real-time requirements related to geolocation, roles and tasks applicable across a range of industries. The firm also provides a range of pre-employment checks via its CVCheck solution. This is delivered via its proprietary technology platform, which includes an employment screening and verification offering. Its geographical segments include Australia and New Zealand. The company serves various industries, including education, financial services, energy and resources, and insurance.
📈 Performance
Price History
-46.48%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.34
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in KYP
7
📊 Total Capital Earnings
$6K
🔃 Average investment frequency
20 weeks
💵 Average investment amount
$3,597
⏰ Last time a customer invested in KYP
1 day
KYP investor breakdown
💵 Income of investors
More than 200k
150k - 200k
36%
100k - 150k
9%
50k - 100k
9%
Less than 50k
45%
👶 Age of investors
18 - 25
26 - 34
29%
35 - 90
71%
🙋 Legal gender of investors
Female
29%
Male
71%
Pearlers who invest in KYP also invest in...
Macquarie Technology Group Ltd. engages in the provision of telecom and hosting services. The company is headquartered in Sydney, New South Wales and currently employs 449 full-time employees. The firm is engaged in the provision of telecommunication, cloud computing, cybersecurity and data center services to corporate and government customers within Australia. The firm operates through three segments: Cloud Services and Government, Data Centres and Telecom. The Cloud Services & Government segment is engaged in the provision of services utilizing the Company and its subsidiaries’ data center facilities to provide cybersecurity, colocation services, public and private cloud and storage to corporate and government customers. The Data Centres segment is engaged in the provision of services utilizing the Company and its subsidiaries’ data center facilities to wholesale customers. The Telecom segment is engaged in the provision of voice and mobile telecommunications services and the provision of services utilizing the Company and its subsidiaries’ data network.
🙌 Performance (5Yr p.a)
9.22%
📊 Share price
$67.38 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
23.41%
📊 Share price
$67.97 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Advanced Braking Technology Ltd. engages in the research, development, design, commercialization, and manufacture of the ABT Failsafe Brakes, ABT Failsafe Emergency Driveline Brakes and Terra Dura Brakes, and associated braking systems. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-05-28. The Company’s principal activities are research and development, commercialization, manufacture and installation of the Failsafe wet sealed braking systems. The company also produces a fully sealed, dry wheel-end range called Terra Dura and specialized hill hold/park brake solutions. Its braking technologies are engineered to address common shortcomings of standard braking systems with solutions for reducing downtime, failsafe / emergency braking, hill hold / park brake systems, heavy trailer brakes, autonomous vehicles, electric vehicles, zero emissions, driveline brakes and others. The company supplies brakes to all seven continents for applications including mining, civil construction, military, freight, agriculture, and recreational/enthusiast off road vehicles. Its range of advanced brake solutions includes Terra Dura, Terra Dura X, Failsafe, Failsafe Emergency and hill hold options.
🙌 Performance (5Yr p.a)
55.76%
📊 Share price
$0.13 AUD
🚗 AUTOMOBILES
XRF Scientific Ltd. manufactures and markets precious metal products, specialized chemicals and instruments for the scientific and analytical industries. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-10-31. These finished goods are primarily used in the preparation of samples for analysis. The firm's segments include Capital Equipment, Precious Metals and Consumables. The Capital Equipment segment manufactures automated fusion equipment, high temperature test and production furnaces, laboratory jaw crushers and general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and industrial platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. Its products and services include Fusion Equipment, Flux & Chemicals, Platinum Labware, Precision Platinum and Lab Equipment. Its subsidiaries include XRF Chemicals Pty Ltd, XRF Labware Pty Ltd and others.
🙌 Performance (5Yr p.a)
134.67%
📊 Share price
$2.32 AUD
🚜 MACHINERY
Cuscal Ltd. engages in the provision of payments and regulated data services. The company is headquartered in Sydney, New South Wales and currently employs 658 full-time employees. The company went IPO on 2024-11-25. The company offers a comprehensive suite of payment infrastructure solutions to a diversified client base. The company enables a range of payment types from physical cards to real-time payments in the payments value chain. The company also provides fraud monitoring solutions. The company operates in the infrastructure layer of the Australian payments market, connecting clients to local payments infrastructure. Its business model includes the provision of three core payments capabilities, including issuing, acquiring and payments. The company offers a comprehensive range of card issuing solutions from debit, credit and prepaid cards to mobile payments and APIs, its end-to-end service and solutions are designed to help the businesses grow. The firm serves various clients in range of industries, including banking, financial services, fintech, and corporates.
📊 Share price
$3.98 AUD
💸 FINANCIALS
Want more shares? Try these...
Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company is headquartered in Sydney, New South Wales. The firm is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.
📊 Share price
$0.08 AUD
NULL STOCK